Albert Lo M.D., Ph.D., is a neurologist/neuroscientist with more than 23 years of clinical trial and research experience in neurodegeneration. He joined Kisbee in 2023 after spending eight years at Eli Lilly and Company, where his role was Vice President in Early Clinical Phase Neurodegeneration. At Lilly, Al was the global clinical leader for multiple Alzheimer’s disease clinical trial programs acting on protocol development, biomarkers translation plans, trial execution, and FDA interactions for anti-amyloid, anti-tau and anti-microglial molecules, such as zagotenemab, BACE inhibitor, and donanemab, which successfully met its primary endpoint for phase 2 and 3 trials. As the Head for the Neuroinflammatory and Neuromuscular Neurology at Lilly, Al led the neuroinflammatory portfolio and SARM1 inhibitor programs and spearheaded clinical development diligence for new and rare disease clinical indications. Most recently he led the emerging ALS clinical development pipeline and strategy across all modalities (large molecules, small molecules and genetic). For biotech acquisitions to further build the neurodegeneration pipeline, Al led the post-acquisition clinical development integration.
Prior to joining industry, Al spent 15 years in academic neurology with a focus on multiple sclerosis, stroke, and ALS, as well as research in Parkinson’s and traumatic brain injury. He was Associate Professor of Neurology, Engineering and Public Health at Brown University as well as Associate Director of the VARRD Center of Excellence for Neurorestoration and Neurotechnology at Providence VA Medical Center. During the seven years before Brown, Al was Assistant Professor of Neurology at Yale University, where he served as the study PI for the VA ROBOTICS phase 2/3 trial testing the MIT-Manus robot intervention for stroke neurorehabilitation. He also engaged in translational research, designing and conducting the initial animal neuroprotection studies examining sodium channel blockade in EAE which were then translated into clinical trial designs in MS. In 2007, Al became the founding Director for Neuroscience research at the Mandell MS Center at Mount Sinai Rehabilitation Hospital in Hartford, CT. He is a Past President of the American Society for Neurorehabilitation, an organization focused on neurorecovery through neuroscience discovery, and from 2019-2021 served as a member the National Advisory Board on Medical Rehabilitation Research, NIH/NCMRR. Al earned his MD/PhD (neuroscience) from Wake Forest University, is a graduate of UC Berkeley, and received his CPH from Harvard University. He completed his internship and neurology residency at Yale University.